Premium
Therapeutic potential of intravenous 67‐gallium in non‐Hodgkin's lymphoma
Author(s) -
Huijgens P. C.,
Jonkhoff A. R.,
Hoekstra O. S.,
Ossenkoppele G. J.,
Teule G. J. J.
Publication year - 1993
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1993.tb00631.x
Subject(s) - pancytopenia , lymphoma , gallium , malignant lymphoma , medicine , isotopes of gallium , scintigraphy , nuclear medicine , gallium 67 scan , non hodgkin's lymphoma , pathology , gastroenterology , chemistry , bone marrow , organic chemistry
67‐gallium accumulates rather selectively in malignant lymphoid tissue. The isotope has a substantial cytotoxic effect in human‐derived cell‐lines. 67‐gallium was given intravenously to 3 patients with end‐stage, resistant large‐cell lymphoma. Evaluation of tumour response was done by physical measurements, and CT‐scanning together with gallium scintigraphy. Three weekly doses of 20, 40 and 60 mCi respectively caused persistent pancytopenia in 1 patient. Panycytopenia was not observed in 2 other patients given two 40 mCi doses 4 weeks apart. In all 3 patients, some response was noted, be it shortlived and different from site to site. 67‐gallium has some cytostatic effect in large cell lymphoma. It seems feasible to start a phase I study to find a tolerable dose to be given every 4 weeks.